SCHEMBL4681003

SCHEMBL4681003

CC1CNCC(C)N1C(=O)OCc1c(F)cc(OCc2cccnc2)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.61
AOC3 Q16853 1/20 0.41
SLC6A4 P31645 1/20 0.41
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
GPR132 Q9UNW8 3/20 0.39
LMNA P02545 1/20 0.39
RECQL P46063 1/20 0.39
GRM2 Q14416 1/20 0.38
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
OPRK1 P41145 1/20 0.37
MMP1 P03956 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP9 P14780 1/20 0.37
MMP13 P45452 1/20 0.37
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4681000 1.00 HTR2C (0.61) HTR2CAOC3SLC6A4BRD4CREBBP
Fumaric Acid SCHEMBL4787130 0.95 HTR2C (0.56) HTR2CAOC3SLC6A4BRD4CREBBP
Fumaric Acid SCHEMBL4787132 0.95 HTR2C (0.56) HTR2CAOC3SLC6A4BRD4CREBBP
Fumaric Acid SCHEMBL4787121 0.95 HTR2C (0.56) HTR2CAOC3SLC6A4BRD4CREBBP
SCHEMBL4677560 0.87 HTR2C (0.51) HTR2CAOC3SLC6A4BRD4CREBBP
SCHEMBL4677567 0.87 HTR2C (0.51) HTR2CAOC3SLC6A4BRD4CREBBP
SCHEMBL4681265 0.85 HTR2C (0.62) HTR2CSLC6A4
SCHEMBL4681268 0.85 HTR2C (0.62) HTR2CSLC6A4
SCHEMBL4678399 0.83 HTR2C (0.64) HTR2C
SCHEMBL4678403 0.83 HTR2C (0.64) HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 HTR2C 289/4885AOC3 4197/4885SLC6A4 892/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 HTR2C 289/4885AOC3 4197/4885SLC6A4 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.